BDX and Swiss‑based Ypsomed announced a new phase of their partnership to develop a 5.5 mL BD Neopak™ XtraFlow™ Glass Prefillable Syringe that is fully compatible with Ypsomed’s YpsoMate® 5.5 autoinjector platform. The collaboration builds on the success of the 2.25 mL syringe and autoinjector pair that was introduced in 2022.
The new syringe features BD’s 8‑mm needle and thinner‑wall cannula technology, which reduces injection time and improves flow for high‑volume, high‑viscosity biologics. The design allows the delivery of larger doses in a single subcutaneous injection, a capability that is increasingly demanded by oncology, autoimmune, rare‑disease and metabolic‑disorder therapies.
For BDX, the expanded partnership strengthens its pharmaceutical systems portfolio and supports its goal of generating recurring revenue from drug‑delivery consumables. The company recently invested $110 million to expand prefillable syringe production in Columbus, Nebraska, with supply expected to begin in mid‑2026. The new syringe will be a key product in that expanded capacity and aligns with BD’s strategy to capture a larger share of the growing biologics market.
Ypsomed’s YpsoMate® 5.5 platform, launched in 2022, was designed to meet the need for large‑volume subcutaneous self‑injections. By integrating BD’s syringe, the partnership expands the platform’s therapeutic reach and positions both companies to serve a broader range of high‑dose biologics, a segment that is projected to grow faster than the overall biologics market.
BD’s financial performance in the most recent quarter—$5.9 billion in revenue and an adjusted diluted EPS of $3.96—illustrates the company’s strong execution in its core segments. The partnership adds a new revenue stream that complements BD’s existing product mix and supports its long‑term growth strategy.
Patrick Jeukenne, worldwide president of BD Pharmaceutical Systems, said the new syringe “directly responds to the growing demand for patient‑friendly solutions in the high‑dose biologics space.” Ulrike Bauer, chief business officer at Ypsomed, added that the collaboration “expands the subcutaneous delivery design space to accommodate high‑dose therapies, both volume and viscosity.”
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.